NCT06289374 Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
| NCT ID | NCT06289374 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imperial College London |
| Condition | Oesophageal Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-02 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-02 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years. There is also increasing research to understand the cancer biology and factors allowing cancers to progress. It is likely there is a relationship between the cancer-specific microbiome, cells related to inflammation, which promotes cancer progression. The BIORESOURCE 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer. This longitudinal study aims to obtain further matched biosamples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response, recurrence and/or long term prognosis.
Eligibility Criteria
Inclusion Criteria: * Aged 18-90 years at the time of initial recruitment * Gastric/oesophageal adenocarcinoma cohort (biopsy proven adenocarcinoma) recruited into BIORESOURCE 1 Exclusion Criteria: * Oesophageal squamous cell carcinoma * Previous oesophageal and gastric resection * History of another cancer within five years. If a new other cancer type is diagnosed within the sampling time frame, no further samples will be taken. * Participants with co-morbidities preventing breath collection * Unable or unwilling to provide informed written consent * Pregnant women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06289374 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Oesophageal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06289374 currently recruiting?
Yes, NCT06289374 is actively recruiting participants. Contact the research team at b.vadhwana@imperial.ac.uk for enrollment information.
Where is the NCT06289374 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT06289374 clinical trial?
NCT06289374 is sponsored by Imperial College London. The trial plans to enroll 100 participants.